Aspen Pharmacare Holdings Limited, a multinational pharmaceutical company specializing in branded and specialty medicines, has launched a new regional headquarters in Riyadh, Saudi Arabia. This expansion is part of a broader strategy to enhance its presence in the Middle East, following a series of investments in key therapeutic areas aimed at meeting market demands.

The establishment of the headquarters aligns with Aspen’s growth strategy, which emphasizes talent development, localization, and partnerships. Daniel Vella Friggieri, the Regional CEO for Europe and the Middle East at Aspen Pharmacare, highlighted the significant changes in Saudi Arabia’s healthcare landscape as an opportunity for the company to align with the Kingdom’s healthcare delivery objectives. He noted that the new headquarters would facilitate the mutual goal setting under the nation’s Vision 2030.

Wesam Nehad, General Manager of Aspen Pharma RHQ, expressed that expanding in Saudi Arabia will allow Aspen to leverage its strong capabilities in the region, including an efficient distribution network, operational excellence, and a highly skilled workforce. Aspen is dedicated to marketing and manufacturing a diverse range of post-patent branded medicines and domestic brands that cater to both hospital and consumer markets, encompassing various product types such as steriles, oral solid doses, liquids, semi-solids, biologicals, and active pharmaceutical ingredients.